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A b s t r a c t  
Nevirapine has been formulated in lipid-based system, a Self Emulsifying Drug Delivery System 
(SEDDS) to target the drug to lymphoid organs where HIV-1 virus resides in large population. 
Nevirapine SEDDS were formulated for enhancement of solubility, dissolution rate and oral 
bioavailability of model drug Nevirapine. Fourteen formulations were prepared using different oils, 
surfactants and co-surfactants. A pseudo ternary phase diagram was constructed to identify the self-
micro emulsification region. Further, the resultant formulations were investigated for clarity, phase 
separation, drug content, % transmittance, globule size, freeze-thaw stability and in vitro dissolution 
studies. On the basis of dissolution profile and other above mentioned studies, F4 was found to be 
the best formulation of Nevirapine SEDDS which contains Capryol 90 (Oil), Tween 80 and PEG 600 
as surfactant co-surfactant respectively. In vivo studies revealed that the oral bioavailability of 
Nevirapine from SEDDS was 2-fold higher compared to that of pure Nevirapine suspension in rats, 
suggesting a significant increase in oral bioavailability of Nevirapine from SEDDS formulation. The 
higher bioavailability might be due to the enhanced solubility of Nevirapine by SEDDS formulation.   
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Introduction 
As oral route for drug administration is most commonly used 
among all the routes of administration due to its convenience, non-
invasiveness and cost effectiveness it become necessary that drug 
should have some aqueous as well as some lipid solubility for their 
absorption [1]. Lipid-based formulation approaches, particularly the 
self-microemulsifying drug delivery system (SMEDDS), are well 
known for their potential as alternative strategies for delivery of 
hydrophobic drugs [2],   which are associated with poor water 
solubility and low oral bioavailability [3-5]. SMEDDS formulations 
are isotropic mixtures of oil, a surfactant, a co-surfactant, and a 
drug. The basic principle of this system is its ability to form fine oil-
in-water (o/w) micro emulsions under gentle agitation following 
dilution by aqueous phases [6].   This spontaneous formation of an 
emulsion in the gastrointestinal tract presents the drug in a 
solubilized form, and the small size of the formed droplet provides 
a large interfacial surface area for drug absorption [7].   Apart from 
solubilization, the presence of lipid in the formulation further helps 
improve bioavailability by affecting the drug absorption. Selection 
of a suitable self- emulsifying formulation depends upon the 
assessment of the solubility of the drug in various components, the 
area of the self-emulsifying region as obtained in the phase 
diagram, and the droplet size distribution of the resultant emulsion 
following self-emulsification [8]. Nevirapine is a non-nucleoside 
reverse transcriptase inhibitor of human immunodeficiency virus, 
type 1 (HIV-1). The drug is practically insoluble in water (0.1 
mg/ml), belongs to Class II as per Biopharmaceutical Classification 
System9 with a log octanol-water partition coefficient (log P) of 2.5 
and a pKa of 2.810. HIV enters the human host via mucosal 
surfaces and is subsequently disseminated throughout the 
lymphatic tissues, a major reservoir of virus throughout the course 
of infection [11, 12].                                              
Materials and methods 
Materials  
Viramune (Nevirapine 200mg) tablets purchased from Boehringer 
Ingelheim, Mumbai. Nevirapine pure drug, Lauroglycol, Labrasol 
was generous gifts from Aurobindo Pharma Limited, Hyderabad, 
India. Castor oil, Capryol 90, Miglynyl 812, Captex 355 and Olive 
oil were obtained from Granules India limited, Hyderabad. Kolliphor 
HS 15, Kolliphor RH 40, Labrasol, Lauroglycol, Labrafil M 2125, 
Labrafil M 1944CS were gifted from BASF, Mumbai. Tween 80, 
Propylene glycol, PEG 400 and PEG 600 were obtained from 
SDFCL, Mumbai. All other chemicals used were of analytical 
grade. 
Methods 
Solubility studies 
It was carried out to determine solubility measurements of 
Nevirapine according to the published method [13] The solubility 
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study was used to find out the suitable oil, surfactant and co-
surfactant that possess good solubilizing capacity for Nevirapine. 
An excess amount (250 mg) of Nevirapine was added into 1 ml of 
each excipient (Oils ă Captex-355, Capryol-90, Castor oil, Miglynyl 
812, Oliec acid, )(surfactants ă Kolliphor HS 15, Kolliphor RH 40, 
Kolliphor PS 80, Kolliphor ELP, Kolliphor EL, Labrasol, Tween-20, 
Tween-80, Cremophor RH 40, Transcutol-P, Labrafac,  Labrafil M 
2125,  Labrafil M 1944cs,  Capmul MCM) (co-surfactants - PEG 
400, PEG 600, Propylene glycol etc) and kept in mechanical 
shaker for 24 hrs and centrifuged at 2500 rpm for 20 min using a 
centrifuge. The supernatant was appropriately diluted with 
methanol, and UV absorbance was measured at 264 nm. 
Concentration of dissolved drug was determined 
spectrophotometrically. 
Pseudoternery phase diagram 
Pseudo ternary phase diagram is used to map the optimal 
composition range for three key excipients according to the 
resulting droplet size following self emulsification, stability upon 
dilution and viscosity. On the basis of the solubility studies of drug 
in oil, surfactants and co-surfactants were used for construction of 
phase diagram. Surfactant and co-surfactant (Smix)  in each group 
were mixed in different volume ratio (1:1, 2:1, 3:1).Oil and 
surfactant/co-surfactant mixture (Smix) were mixed thoroughly in 
different volume ratios 1:9 to 9:1 (1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 
1:2, and 1:1) and (9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, and 2:1) w/w. The 
mixture of oil, surfactant and co-surfactant at certain ratios were 
titrated with water by drop wise addition under gentle agitation. 
Deionized water was used as diluting medium and added into the 
formulation. The proper ratio one excipient to another in the 
SMEDDS formulation was analysed. Pseudo ternary plots were 
constructed using Chemix software. 
Development of SMEDDS formulation 
A series of SMEDDS formulation for Nevirapine were prepared 
based on solubility studies, pseudo ternary phase diagram and 
visual observation. Here, Capryol 90 (Capryol PGMC) was used oil 
phase and Tween 80 and PEG 600 were used as surfactant and 
co-surfactant respectively. The composition was given in the Table. 
In brief, Nevirapine (200 mg) was added in accurately weighed 
amount of oil into screw ă capped glass vial and heated in a water 
bath at 40ĈC. The surfactant and co-surfactant were added to the 
oil mixture using positive displacement pipette and stirred with 
magnetic bar. The formulation was further sonicated for 15mins 
and stored at room temperature until its use in subsequent studies. 
 
Table 1: Formulation trials of liquid SMEDDS 
 
Smix 
(Surfactant: 
Co-surfactant) 
 
 
Oil:Smix 
 
 
Formulation 
Code 
Oil 
(Capryol 90 ) 
(ml) 
Surfactant 
(Tween 80) 
(ml) 
 
Co-surfactant 
(PEG 600) 
(ml) 
 
 
1:1 
1:9 F1 0.400 1.80 1.80 
1:8 F2 0.444 1.776 1.776
1:7 F3 0.5 1.750 1.750
1:6 F4 0.541 1.713 1.713
 
2:1 
1:9 F5 0.400 2.400 1.200
1:8 F6 0.444 2.368 1.184
1:7 F7 0.500 2.332 1.166
1:6 F8 0.571 2.284 1.142
1:5 F9 0.666 2.220 1.11 
3:1 
1:9 F10 0.4 2.7 0.9 
1:8 F11 0.444 2.664 0.888
1:7 F12 0.5 2.625 0.875
1:6 F13 0.571 2.569 0.856
1:5 F14 0.666 2.497 0.832
 
Freeze thawing 
Freeze thawing was employed to evaluate the stability of 
formulations. The formulations were subjected to 3 to 4 freeze-
thaw cycles, which included freezing at ă 4 ĈC for 24 hours followed 
by thawing at 40 ĈC for 24 hours. Centrifugation was performed at 
3000 rpm for 5 minutes. The formulations were then observed for 
phase separation. Only formulations that were stable to phase 
separation were selected for further studies. 
% Transmittance 
% Transmittance of Nevirapine SMEDDS was measured by U.V 
spectroscopy at wavelength of 600 to 660nm. A graph for %particle 
range vs. formulations was plotted.  
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Determination of drug content  
SMEDDS equivalent to 200mg of Nevirapine were weighed 
accurately and dissolved in 100ml of 0.1N HCL. The solution was 
filtered, diluted suitable and drug content was analyzed at λmax 264 
nm against blank by UV spectrometer. The actual drug content was 
calculated using the following equation as follows: 
                                      Actual amount of drug in SMEDDS 
% Drug content = ------------------------------------------------------  X 100 
                                  Theoretical amount of drug in SMEDDS  
In-vitro dissolution studies  
The release of drug from liquid SMEDDS formulations and pure 
drug was determined using a US Pharmacopoeia Type II 
dissolution apparatus. The liquid SMEDDS formulations were 
directly placed into the medium [14]. The dissolution media is 0.1N 
HCL, and temperature of the dissolution medium was maintained 
at 370C operated at 75 rpm. An aliquot of 5 ml was withdrawn at 
predetermined intervals 2, 5, 10, 15, 20, 25, 30, 45, and 60 mins 
and filtered through 0.45-μm pore size membrane filters. The 
removed volume was replaced each time with 5 ml of fresh 
medium. The concentrations were assayed spectrophotometrically 
at 264nm. 
Characterization of SEDDS 
Drug-excipient compatibility studies 
Fourier transform infrared spectroscopy (FTIR)   
The IR spectra of pure drug, excipients and optimized formulations 
were recorded using FT-IR (Shimadzu 8400-S) with diffuse 
reflectance principle. Sample preparation involved, drying of 
potassium bromide (KBr), drug and excipients in the oven to get rid 
of any moisture content then mixing the sample with KBr by 
triturating in glass mortar. Finally preparing of pellet and placing in 
the sample holder. The spectrum was scanned over a frequency 
range 4000 ă 400 cm-1 [15]. 
Differential scanning calorimetry (DSC) 
Differential scanning calorimetry (DSC) studies were carried out 
using DSC 60, having TA60 software, Shimadzu, Japan. 
Accurately weighed samples were placed on aluminium plate, 
sealed with aluminium lids and heated at a constant rate of 5ÀC 
/min, over a temperature range of 0 to 250ÀC [16]. 
Determination of droplet size 
The average droplet size of Nevirapine SMEDDS formulations 
were determined by Photon correlation spectroscopy (Malvern 
Instrument UK) able to measure sizes between 10 and 5000 nm. 
The selected formulations were diluted with deionized water and 
placed in an electrophoretic cell for measurement [17]. 
Determination of zeta potential  
The emulsion stability is directly related to the magnitude of the 
surface charge. In conventional SMEDDS, the charge on an oil 
droplet is negative because of the presence of free fatty acids. The 
zeta potential of the diluted SMEDDS formulation was measured 
using a zeta meter system. The SMEDDS were diluted with a ratio 
1:2500 (v/v) with distilled water and mixed with magnetic stirrer. 
Zeta-potential of the resulting micro emulsion was determined 
using a Malvern Zetasizer [18]. 
Scanning electron microscopy 
The surface and shape characteristics of pellets were determined 
by scanning electron microscopy (SEM) (HITACHI, S-3700N). 
Photographs were taken and recorded at suitable magnification. 
Stability studies 
The SMEDDS formulations were put into empty hard gelatin 
capsules and subjected to stability studies at 40ĈC/75% RH. 
Samples were charged in stability chambers (Thermo lab, Mumbai, 
India) with humidity and temperature control. They were withdrawn 
at specified Accelerated conditions for 6months. Dissolution 
studies and drug content of the capsules was analyzed using a 
previously developed and validated stability-indicating UV method. 
In vivo bioavailability studies 
Animals 
Healthy Wistar rats were (Weighing 150-180 g) selected for this 
study, all the animals were healthy during the period of the 
experiment. All efforts were made to maintain the animals under 
controlled environmental conditions (Temperature 250C, Relative 
Humidity 45% and 12 h alternate light and dark cycle) with 100% 
fresh air exchange in animal rooms, uninterrupted power and water 
supply.  Rats were fed with standard diet and water ad libitum. The 
protocol of this study was approved by the institutional animal 
ethics committee. 
Study Design 
Healthy Wistar rats were divided in to two groups at random 
containing six animals each. The rats were fasted for 24 hours prior 
to the experiments. After 4 hours of dosing, foods were reoffered. 
First group was administered with pure Nevirapine (as such) made 
suspension with 0.5% methocel and second group was 
administered liquid SMEDDS diluted in 0.5% methocel by oral 
route at a dose of 200mg equivalent to animal body weight. Then, 
500 øL blood samples were collected from the retro-orbital vein 
using a heparinized needle (18-20 size) at 0, 0.25, 0.50, 1.00, 1.50, 
2.00, 2.50, 3.00, 4.00, 5.00, 6.00, 8.00,16.00 and 24.00 hrs post 
dose and transferred into Eppendorf tubes containing heparin in 
order to prevent blood clotting. Plasma was separated by 
centrifugation of the blood at 5000 rpm in cooling centrifuge for 
5min to 10 minutes and stored frozen at î20ĈC until analysis.  
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high clarity of microemulsion. In case of other systems %T values 
were less than 99% suggesting less clarity of microemulsions. This 
may be due to greater particle size of the formulation. Due to 
higher particle size, oil globules may reduce the transparency of 
microemulsion and thereby values of %T. The results of %T are as 
shown in Table 2. The drug content of the prepared SMEDDS was 
found to be in the range of 91.30 - 98.63%. Maximum % drug 
content i.e. 98.63% was found in the formulation F4. The results of 
visual observation % Transmittance and drug content were shown 
in Table 2. 
 
Table 2: % Transmittance of different formulations 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In-vitro dissolution studies of SMEDDS 
The results of in vitro dissolution comparisons of SMEDDS 
formulations are summarized in Table 3, 4 and Figure 7, 8.  The 
faster dissolution from SMEDDS may be attributed to the fact that 
in this formulation, the drug is a solubilized form and upon 
exposure to dissolution medium results in small droplet that can 
dissolve rapidly in the dissolution medium. The release from liquid 
SMEDDS formulation F4 was faster than other SMEDDS 
formulations and pure drug substance indicating influence of 
droplet size on the rate of drug dissolution. 
 
 
 
       
 
 
S. No. Formulation Code % Drug content % Transmittance 
1 F1 94.36 99.959 
2 F2 94.21 99.387 
3 F3 92.53 99.867 
4 F4 98.63 99.971 
5 F5 91.95 99.678 
6 F6 92.20 99.225 
7 F7 94.67 99.619 
8 F8 93.75 99.536 
9 F9 91.60 99.951 
10 F10 92.64 99.541 
11 F11 94.53 99.954 
12 F12 93.26 99.052 
13 F13 91.30 99.631 
14 F14 94.59 99.303 
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Table 3:  in vitro Cumulative % Drug Release for Formulations (F1-F8), pure drug and innovator 
 
 
 
 
Time 
(mins) 
Cumulative % drug release
 
Pure drug Innovator 
product 
(Viramune 
200mg) 
 
F1 
 
F2 F3 F4 F5 
 
F6 
 
F7 F8 
0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0
2 2.21μ0.12 40.03μ0.51 51.68μ0.32 37.62μ0.55 38.09μ0.25 53.01μ0.21 31.45μ0.56 35.56μ0.51 50.62μ0.42 28.03μ0.28
5 6.34μ0.42 65.21μ0.42 63.94μ0.56 53.43μ0.75 50.78μ0.15 68.31μ0.54 52.34μ0.52 48.91μ0.55 63.75μ0.12 46.71μ0.24
10 10.91μ0.24 74.63μ0.32 75.50μ0.32 64.22μ0.32 65.05μ0.41 80.63μ0.52 63.73μ0.75 64.24μ0.53 78.92μ0.53 57.82μ0.26
15 14.78μ0.56 77.99μ0.22 76.43μ0.24 70.84μ0.52 74.82μ0.24 84.62μ0.58 66.36μ0.32 70.89μ0.23 80.34μ0.75 60.01μ0.52
20 17.43μ0.52 78.58μ0.43 77.60μ0.52 72.38μ0.42 79.36μ0.32 86.55μ0.69 67.13μ0.25 71.04μ0.52 81.68μ0.59 62.34μ0.24
25 20.11μ0.35 79.39μ0.77 77.95μ0.15 72.96μ0.36 80.21μ0.54 88.31μ0.55 67.82μ0.24 72.01μ0.23 82.74μ0.24 64.78μ0.32
30 23.32μ0.52 80.57μ0.45 78.43μ0.32 73.84μ0.41 81.36μ0.55 88.92μ0.72 68.81μ0.21 72.33μ0.21 82.99μ0.53 65.52μ0.74
45 31.57μ0.75 81.24μ0.32 79.05μ0.16 75.06μ0.35 81.75μ0.51 91.25μ0.52 70.08μ0.32 73.68μ0.56 83.61μ0.31 65.09μ0.12
60 32.84μ0.55 81.76μ0.28 81.26μ0.15 75.95μ0.52 82.64μ0.21 93.64μ0.42 72.22μ0.21 74.53μ0.62 84.14μ0.54 67.34μ0.23
 
Table 4:  in vitro Cumulative % Drug Release for Formulations (F9-F14), pure drug and innovator 
 
 
 
Time 
(mins) 
Cumulative % drug release
Pure drug Innovator 
product 
(Viramune 
200mg) 
 
F9 F10 F11 F12 F13 
 
F14 
0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0 0μ0
2 2.21μ0.12 40.03μ0.51 53.02μ0.25 41.24μ0.42 34.42μ0.23 31.33μ0.25 42.63μ0.42 53.34μ0.42
5 6.34μ0.42 65.21μ0.42 68.79μ0.36 61.82μ0.26 50.61μ0.29 69.06μ0.54 53.34μ0.54 64.32μ0.85
10 10.91μ0.2
4 
74.63μ0.32 73.54μ0.29 71.54μ0.28 61.33μ0.53 77.85μ0.26 66.46μ0.85 73.65μ0.68 
15 14.78μ0.56 77.99μ0.22 74.61μ0.58 72.93μ0.65 65.54μ0.42 79.62μ0.19 71.97μ0.52 75.83μ0.52 
20 
17.43μ0.5
2 78.58μ0.43 75.02μ0.27 73.08μ0.32 66.74μ0.29 81.13μ0.42 72.24μ0.54 76.15μ0.28 
25 20.11μ0.3
5 
79.39μ0.77 75.94μ0.52 73.64μ0.85 66.91μ0.79 81.95μ0.75 72.86μ0.32 76.84μ0.54 
30 23.32μ0.52 
80.57μ0.45 76.81μ0.56 75.17μ0.45 67.35μ0.56 82.22μ0.42 74.34μ0.33 77.68μ0.41 
45 
31.57μ0.7
5 
81.24μ0.32 
78.12μ0.75 76.02μ0.12 68.04μ0.18 83.67μ0.35 75.91μ0.18 78.92μ0.52 
60 32.84μ0.5
5 
81.76μ0.28 80.31μ0.32 77.13μ0.21 68.72μ0.86 84.85μ0.62 76.37μ0.15 79.31μ0.75 
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Figure 7: in vitro Cumulative % Drug Release for Formulations (F1-F8), pure drug and innovator 
 
 
Figure 8: in vitro Cumulative % Drug Release for Formulations (F9-F14), pure drug and innovator 
 
Particle size analysis of SMEDDS 
The particle size of the emulsion is a crucial factor in self-
emulsification performance because it determines the rate and 
extent of drug release as well as absorption. The average particle 
size of SMEDDS for transparent micro-emulsions should be less 
than 50nm. The particle size of the optimized SMEDDS formulation 
was found to be 19.5nm indicating all the particles were in the 
micrometer range. Figure 9 represents the particle size analysis of 
optimized SMEDDS formulation. 
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Figure 9: Particle size analysis of optimized Nevirapine SMEDDS formulation (F4) 
 
Zeta potential of SMEDDS 
Zeta potential has got practical application in the stability of 
emulsion since it governs the degree of repulsion between 
adjacent, similarly charged and dispersed droplets.  In general, the 
zeta potential value of μ30ԜmV is sufficient for the stability of a 
micro emulsion. The zeta potential of the optimized SMEDDS 
formulation was found to be -32.6 mV which complies with the 
requirement of the zeta potential for stability. Figure 10 represents 
the particle size analysis of optimized SMEDDS formulation. 
 
 
 Figure 10: Zeta potential of the optimized Nevirapine SMEDDS formulation (F4)Drug excipient interactions by FTIR spectroscopy 
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Figure 11: FTIR Spectroscopy of Nevirapine pure drug 
 
 
Figure 12: FTIR Spectroscopy of Nevirapine + Capryol 90 (oil) 
 
 
Figure 13: FTIR Spectroscopy of Nevirapine + Tween 80 (surfactant) 
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Figure 14: FTIR Spectroscopy of Nevirapine optimized formulation (F4) 
 
Interpretation of FTIR Data 
FT-IR spectrums are mainly used to determine if there is any 
interaction between the drug and any of the excipient used. The 
FTIR spectra of pure Nevirapine (Figure 11) displayed bands at 
3097cm-1 due to N-H stretch, at 1640cm-1 due to C=O stretching, 
at 1290cm-1 due to aromatic amine group C-N stretching. The 
spectra also showed bands at 1290cm-1 due to C-N bending. The 
FTIR spectrum of SMEDDS (Figure 14)  containing Nevirapine 
exhibited characteristic bands consistent with the molecular 
structure of Nevirapine such as bands at 3095 cm-1 due to N-H 
stretch, at  1645cm-1 due to C=O stretching, at 1288 cm-1 due to 
aromatic amine group C-N stretching. FTIR spectrum of Nevirapine 
+ Capryol 90 and Nevirapine + Tween 80 are shown in Figure 12 & 
13 respectively. Thus, the presence of characteristic absorption 
bands of Nevirapine and the SMEDDS containing Nevirapine 
suggest that there was no interaction between the drug and 
excipients used in the formulation. 
Drug excipient interactions by DSC Studies 
The DSC thermo grams of Pure Nevirapine showed in Figure 15, 
sharp endothermic peak at melting point (2450C), indicating that 
the drug is highly crystalline. The absence of drug peak in the 
SEDDS optimized formulation F4 indicating the drug was in 
amorphous form. 
 
 
Figure 15: DSC thermo grams of Nevirapine pure drug (A) and SEDDS optimized formulation F4 (B).Scanning electron microscopy (SEM) for 
optimized SMEDDS (F4) 
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Scanning electron microscope pictures (Figure 16) of optimized formulation (F4) indicated that the particles are spherical and rough surface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Scanning Electron Microscopy of optimized SMEDDS (F4) 
 
Stability studies 
The optimized Nevirapine SEDDS (F4) was poured into hard 
gelatin capsules as the final dosage form. The developed 
formulation was subjected to stability studies for 6 months to 
evaluate its stability and the integrity of the dosage form. There 
was no significant change in the drug content, drug release. It was 
also seen that the formulation was compatible with the hard gelatin 
capsule shells, as there was no sign of capsule shell deformation. 
There was no significant change in the appearance or micro 
emulsifying property. Thus, these studies confirmed that the 
formulation was stable and its compatibility with hard gelatin 
capsules. 
In vivo bioavailability studies 
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Figure 17: Plasma Concentrations of Nevirapine optimized SMEDDS (F4) and Nevirapine pure drug at different time intervals (Mean μ SD, n = 6) 
 
Table 5: Pharmacokinetic Parameters of Nevirapine optimized SMEDDS (F4) Nevirapine optimized SMEDDS (F4) and pure drug 
 
Pharmacokinetic Parameters Nevirapine optimized SMEDDS (F4) Nevirapine Pure drug 
C max (øg/ml) 3.9μ0.05 2.02μ0.35
AUC 0-t (øg.hr/ml) 44.7μ0.06 22.1μ0.05
AUC 0-inf (øg.hr/ml) 45.25μ0.08 24.25μ0.07
T max (hr) 1.00μ0.05 1.50μ0.03
t 1/2 (hr) 2.02μ0.04 3.15μ0.01
K el (hr -1) 0.191μ0.05 0.364μ0.02
 
Pharmacokinetic parameters comparison for Nevirapine 
pure drug suspension and optimized SMEDDS (F4) 
Figure 17 shows the plasma concentrationătime curve in Wistar 
rats after a single oral dose of Nevirapine optimized SMEDDS (F4) 
as compared to Nevirapine pure suspension. At all the indicated 
time points, the Nevirapine plasma concentrations in rats treated 
with optimized formulation (F4) was significantly higher than those 
treated with pure drug. Pharmacokinetic parameters of Nevirapine 
after oral administration of the two formulations in Wistar rats are 
shown in Table 5.  
As can be seen from the above table, Cmax of the optimized 
formulation (F4) 3.9μ0.05øg/ml was significant (p<0.05) as 
compared to the pure drug suspension formulation 
2.02μ0.35øg/ml. Tmax of both optimized formulation (F4) and pure 
drug suspension was 1.00μ0.05hr and 1.50μ0.03hr, respectively. 
AUC is an important parameter in evaluating bioavailability of drug 
from dosage form, as it represents the total integrated area under 
the blood concentration time profile and represents the total 
amount of drug reaching the systemic circulation after oral 
administration. AUC0-¥ infinity for optimized formulation (F4) was 
higher 45.25μ0.08 øg.hr/ml than the pure drug suspension 
formulation 24.25μ0.07øg.hr/ml. Statistically, AUC0-t of the 
optimized SMEDDS (F4) (44.7μ0.06) was significantly higher 
(p<0.05) as compared to pure drug suspension formulation 
(22.1μ0.05). Higher amount of drug concentration in blood 
indicated better systemic absorption of Nevirapine optimized 
formulation (F4) as compared to the pure drug suspension 
formulation. Calculated concentration was found to be more for 
optimized formulation (F4) compared with pure drug of Nevirapine. 
Summary and conclusion 
Our studies highlighted the potential of using SEDDS as an 
efficient strategy for the oral delivery of hydrophobic Nevirapine. 
Nevirapine was formulated as SEDDS based on the oil solubility 
studies and ternary phase diagrams. From this study it was 
concluded that, prepared SEDDS was thermodynamically stable 
with good self emulsification efficiency and having globule size in 
nanometric range which may be physiologically stable. On the 
basis of different evaluation parameters and dissolution studies F4 
was found to be optimized formulation which contains Capryol 90 
as oil, Tween 80 and PEG 600 as a surfactant and co-surfactant 
respectively. FTIR analysis revealed that, there was no interaction 
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between the drug and polymers. From DSC studies it was 
concluded that the optimized formulation was in amorphous state, 
which influenced the enhancement of solubility. Results of SEM 
indicated that the homogeneous and spherical droplets in micro 
emulsion were observed. In-vitro drug release of optimized SEDDS 
(F4) was much higher than that of pure Nevirapine and marketed 
formulation. Hence it was concluded that SEDDS can be efficiently 
formulated to enhance dissolution rate of poorly soluble drug such 
as Nevirapine. The pharmacokinetic data indicated that the 
Nevirapine SEDDS have better in vivo absorption compared to 
pure drug suspension. The higher bioavailability might be due to 
the enhanced solubility of Nevirapine by SEDDS formulation.  The 
oral bioavailability study of optimized SEDDS (F4) showed 
improvement by a factor of 2 - fold compared to the pure drug 
suspension in rats. Thus Nevirapine with SMEDDS may be used 
for improvement of oral bioavailability of drugs with poor water 
solubility and low oral bioavailability. 
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